Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the globa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Main Authors: Kumar, Shaji, Moreau, Philippe, Hari, Parameswaran, Mateos, Maria‐Victoria, Ludwig, Heinz, Shustik, Chaim, Masszi, Tamas, Spencer, Andrew, Hájek, Roman, Romeril, Kenneth, Avivi, Irit, Liberati, Anna M., Minnema, Monique C., Einsele, Hermann, Lonial, Sagar, Berg, Deborah, Lin, Jianchang, Gupta, Neeraj, Esseltine, Dixie‐Lee, Richardson, Paul G.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Haematological Malignancy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5574012/
https://ncbi.nlm.nih.gov/pubmed/28485007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14733
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares